Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 7/20 | 0.71 |
| ▸ | ACE | P12821 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | CTSS | P25774 | 2/20 | 0.61 |
| ▸ | CTSL | P07711 | 1/20 | 0.61 |
| ▸ | CTSB | P07858 | 1/20 | 0.61 |
| ▸ | CTSK | P43235 | 1/20 | 0.61 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.58 |
| ▸ | MME | P08473 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21244275 | 1.00 | REN (0.71) | RENACEMAPK1CTSSCTSL | |
| SCHEMBL3824374 | 1.00 | REN (0.71) | RENACEMAPK1CTSSCTSL | |
| SCHEMBL17629479 | 1.00 | REN (0.71) | RENACEMAPK1CTSSCTSL | |
| SCHEMBL19341935 | 1.00 | REN (0.71) | RENACEMAPK1CTSSCTSL | |
| SCHEMBL6897460 | 0.99 | REN (0.73) | RENACEMAPK1CTSSCTSL | |
| SCHEMBL3046634 | 0.99 | REN (0.73) | RENACEMAPK1CTSSCTSL | |
| SCHEMBL9101385 | 0.99 | REN (0.73) | RENACEMAPK1CTSSCTSL | |
| SCHEMBL5994686 | 0.99 | REN (0.73) | RENACEMAPK1CTSSCTSL | |
| SCHEMBL9101393 | 0.99 | REN (0.73) | RENACEMAPK1CTSSCTSL | |
| SCHEMBL9551232 | 0.96 | REN (0.73) | RENACEMAPK1CTSSCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112794879-B | Synthesis and application of Glu-Leu-Phe-Tyr-Val pentapeptide | 首都医科大学 | 2022-09-02 | — | — | CN | claimed |
| CN-112812152-B | Synthesis and anti-inflammatory application of Glu-Leu-Phe-Tyr-Val pentapeptide | 首都医科大学 | 2022-09-02 | — | — | CN | claimed |
| CN-112812152-B | Synthesis and anti-inflammatory application of Glu-Leu-Phe-Tyr-Val pentapeptide | 首都医科大学 | 2022-09-02 | — | — | CN | disclosed |
| CN-112794879-B | Synthesis and application of Glu-Leu-Phe-Tyr-Val pentapeptide | 首都医科大学 | 2022-09-02 | — | — | CN | disclosed |
| US-10689416-B2 | Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer | UNITY BIOTECHNOLOGY, INC. (US) | 2020-06-23 | — | — | US | disclosed |
| US-10519197-B1 | Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer | UNITY BIOTECHNOLOGY, INC. (US) | 2019-12-31 | — | — | US | disclosed |
| US-20190248837-A1 | Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer | UNITY BIOTECHNOLOGY, INC. | 2019-08-15 | — | — | US | disclosed |
| CN-109824755-A | N- tertbutyloxycarbonyl-L- leucyl-L-phenylalanine methyl esters production method | 湖南华腾制药有限公司 | 2019-05-31 | — | — | CN | disclosed |
| US-20180037606-A1 | METHODS OF MAKING CARFILZOMIB AND INTERMEDIATES THEREOF | APICORE US LLC (US) | 2018-02-08 | — | — | US | disclosed |
| US-9839665-B2 | Aminostatin derivatives for the treatment of arthrosis | MERCK PATENT GMBH (DE) | 2017-12-12 | — | — | US | disclosed |
| US-9839665-B2 | Aminostatin derivatives for the treatment of arthrosis | MERCK PATENT GMBH (DE) | 2017-12-12 | — | — | US | disclosed |
| US-20070105786-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2007-05-10 | — | — | US | disclosed |
| US-20060094718-A1 | 2-Morpholinocarbonyloxy-),5-(phenylethenyl,N-((3,5-bistrifluoromethyl-)phenyl)-benzamide; inhibitors of nuclear factor kappa B activation; cytokine suppressive antiinflammatory drugs(interleukin (IL-1, IL-6, IL-8) inhibitors); tumor necrosis factor (TNF-alpha) inhibitors; side effects reduction | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-05-04 | — | — | US | disclosed |
| WO-2005111008-A2 | COMPOUNDS FOR ENZYME INHIBITION | PROTEOLIX, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| EP-1512397-A1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-09 | — | — | EP | disclosed |
| US-5821331-A | INHIBIT THE PROTEOLYTIC ACTIVITY OF PROTEASES | ELI LILLY AND COMPANY (US) | 1998-10-13 | — | — | US | disclosed |
| US-5514778-A | ENZYME INHIBITORS OF PROTEOLYTIC ENZYMES FOR RHINOVIRUSES | ELI LILLY AND COMPANY (US) | 1996-05-07 | — | — | US | disclosed |
| EP-0632051-A1 | Anti-picornaviral agents | ELI LILLY AND COMPANY (US) | 1995-01-04 | — | — | EP | disclosed |
| US-4465668-A | CONTAINING A BONDED OLIGOPEPTIDE GROUP | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1984-08-14 | — | — | US | disclosed |
| EP-0060422-A2 | Method for improving intestinal absorption of cephalosporin derivatives | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1982-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094718-A1 | 2-Morpholinocarbonyloxy-),5-(phenylethenyl,N-((3,5-bistrifluoromethyl-)phenyl)-benzamide; inhibitors of nuclear factor kappa B activation; cytokine suppressive antiinflammatory drugs(interleukin (IL-1, IL-6, IL-8) inhibitors); tumor necrosis factor (TNF-alpha) inhibitors; side effects reduction | IL1A, TNF, NFKBIA | REN 640/4885ACE 773/4885MAPK1 126/4885 |
| US-20180037606-A1 | METHODS OF MAKING CARFILZOMIB AND INTERMEDIATES THEREOF | PAICS, RCE1, CPSF1 | REN 432/4885ACE 357/4885MAPK1 3553/4885 |
| US-20190248837-A1 | Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer | PSMB1, PSMB7, PSMB5 | REN 1650/4885ACE 983/4885MAPK1 1324/4885 |
| US-20070105786-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | ANPEP, PSMB1, PSMB3 | REN 976/4885ACE 611/4885MAPK1 2653/4885 |
| US-10689416-B2 | Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer | PSMB1, PSMB7, PSMB5 | REN 1650/4885ACE 983/4885MAPK1 1324/4885 |
| US-10519197-B1 | Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer | PSMB1, PSMB7, PSMB5 | REN 1650/4885ACE 983/4885MAPK1 1324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.